Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris

American Journal of Cardiology

Volumn 95, Issue 3, 2005, Pages 311-316

  Rousseau, Michel F ^a   Pouleur, Hubert ^b   Cocco, Giuseppe ^c   Wolff, Andrew A ^d  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b PFIZER INC   (United States)

^c Solbadklinik   (Switzerland)

^d CV THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; NITRIC ACID DERIVATIVE; RANOLAZINE; SHORT ACTING DRUG;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHENIA; BLOOD PRESSURE MONITORING; BLOOD TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RELEASE; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HEMODYNAMIC MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT WITHDRAWAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANALYSIS OF VARIANCE; ANGINA PECTORIS; ATENOLOL; BLOOD PRESSURE; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EXERCISE TEST; FEMALE; HEART RATE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PIPERAZINES; TREATMENT OUTCOME;

EID: 12844280008     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.09.025     Document Type: Article

References (8)

1. B.R. Chaitman, C.J. Pepine, J.O. Parker, J. Skopal, G. Chumakova, J. Kuch, W. Wang, S.L. Skettino, A.A. Wolff Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 291 2004 309 316
2. B.R. Chaitman, S.L. Skettino, J.O. Parker, P. Hanley, J. Meluzin, J. Kuch Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with severe coronary artery disease and chronic angina: the MARISA trial J Am Coll Cardiol 43 2004 1375 1382
3. G. Cocco, M.F. Rousseau, T. Bouvy, P. Cheron, G. Williams, J.M. Detry, H. Pouleur Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem J Cardiovasc Pharmacol 20 1992 131 138
4. C.J. Pepine, A.A. Wolff A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents Ranolazine Study Group Am J Cardiol 84 1999 46 50
5. W.A. Wallace, K.L. Wellington, M.A. Chess, C.S. Liang Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris Am J Cardiol 73 1994 23 28
6. M.P. Chandler, W.C. Stanley, H. Morita, G. Suzuki, B.A. Roth, B. Blackburn, A. Wolff, H.N. Sabbah Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure Circ Res 91 2002 278 280
7. R.J. Gibbons, J. Abrams, K. Chatterjee, J. Daley, P.C. Deedwania, J.S. Douglas, T.B. Ferguson Jr, S.D. Fihn, T.D. Fraker Jr, J.M. Gardin ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina) J Am Coll Cardiol 41 2003 159 168
8. S.C. Beinart, A.E. Sales, J.A. Spertus, M.E. Plomondon, N.R. Every, J.S. Rumsfeld Impact of angina burden and other factors on treatment satisfaction after acute coronary syndromes Am Heart J 146 2003 646 652